APP and Alzheimer disease: SPON1, significantly increased in sDS, is reported to prohibit enzymatic release of amyloid by binding to APP,73 thereby possibly mediating cognitive decline and structural brain changes in AD,74, 75 and increase in CSF in autosomal‐dominant AD, as early as 30 years prior symptom onset.76